Suchergebnisse - "Motoi, Noriko"

PubPharm (20)

1

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

enthalten in: Anticancer research | 2024

von Fuchizawa, H. | Ando, K. | Motoi, N. | +10

2

Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma

enthalten in: Cancer science | 2023

von Sugawara, K. | Fukuda, T. | Kishimoto, Y. | +7

3

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients

enthalten in: Clinical lung cancer | 2022

von Shimoda, Y. | Shibaki, R. | Yoshida, T. | +12

4

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Shirasawa, M. | Yoshida, T. | Imabayashi, T. | +13

CommentIn: Eur J Cancer. 2022 May;167:149-151. - PMID 35307255

5

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Shirasawa, M. | Yoshida, T. | Shimoda, Y. | +18

6

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

enthalten in: Anticancer research | 2021

von Shimoda, Y. | Yoshida, T. | Shirasawa, M. | +11

7

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Yoh, K. | Matsumoto, S. | Furuya, N. | +14

8

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma

enthalten in: Clinical lung cancer | 2021

von Shirasawa, M. | Yoshida, T. | Takayanagi, D. | +16

9

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Mino-Kenudson, M. | Le Stang, N. | Daigneault, J. | +36

ErratumIn: J Thorac Oncol. 2021 May 9;:. - PMID 33980465

10

Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC

enthalten in: Clinical lung cancer | 2021

von Takeyasu, Y. | Yoshida, T. | Shibaki, R. | +7